SABBY MANAGEMENT, LLC
Q1 2014 13F-HR Holdings
Net value change ($000)
+215,275
(13.7%)
New positions
52
Sold out positions
46
Turnover %
96.2%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| OXYGEN BIOTHERAPEUTICS INC | 11,770 | NEW |
| Bio-Path Holdings Inc. | 8,781 | NEW |
| OPK | 7,747 | NEW |
| XBI | 6,233 | NEW |
| PEREGRINE PHARMACEUTICALS IN | 6,017 | NEW |
| QURE | 5,505 | NEW |
| AMGN | 5,219 | NEW |
| REGN | 5,162 | NEW |
| GILD | 5,126 | 87.4% |
| TMO | 4,645 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| MANNKIND CORP | -20,485 | -100.0% |
| *AEGERION PHARMACEUTICALS INC | -6,689 | -80.8% |
| MEDIVATION | -4,788 | -100.0% |
| TWTR | -4,602 | -100.0% |
| TEKMIRA PHARMACEUTICALS CORP | -4,138 | -100.0% |
| ANTHERA PHARMACEUTICALS INC | -2,960 | -56.2% |
| ONCOGENEX PHARMACEUTICALS IN | -2,942 | -100.0% |
| ACAD | -2,652 | -19.1% |
| *KYTHERA BIOPHARMACEUTICALS I | -2,466 | -100.0% |
| ENTA | -2,345 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
1,571,090
(88.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|